<DOC>
	<DOCNO>NCT00005051</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient advanced ovarian epithelial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity tolerance sequential therapy prolong - Determine response rate time progression patient - Determine relative pharmacokinetics IV prolong oral administration topotecan patient compare pharmacodynamics topo-1 inhibition give IV oral route . OUTLINE : - Regimen A : Patients receive cisplatin IV 60-90 minute day 1 course . Topotecan IV administer continuously day 1-14 course 1 . Oral topotecan administer twice daily day 1-14 course 2 , 3 , 4 . Treatment repeat every 28 day 4 course . - Regimen B : After completion regimen A , patient receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4 course . PROJECTED ACCRUAL : A total 30 patient ( 15 per arm ) accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced ovarian epithelial carcinoma , regardless quantity disease postsurgery Stage IC , II , III , IV PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGOT great 3 time upper limit normal Bilirubin great 2.0 mg/dL No clinically significant hepatic disorder Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min No clinically significant renal disorder Cardiovascular : No clinically significant cardiovascular condition Other : Normal GI function allow reliable administration oral medication No active infection require systemic medical therapy within past week No clinically significant medical condition ( e.g. , endocrine/metabolic autoimmune disorder ) No prior malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No dementia alter mental status would preclude consent Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy ovarian epithelial carcinoma Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy ovarian epithelial carcinoma Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>